BR112022021203A2 - Modulação de enzima e via com compostos sulfidrila e seus derivados - Google Patents

Modulação de enzima e via com compostos sulfidrila e seus derivados

Info

Publication number
BR112022021203A2
BR112022021203A2 BR112022021203A BR112022021203A BR112022021203A2 BR 112022021203 A2 BR112022021203 A2 BR 112022021203A2 BR 112022021203 A BR112022021203 A BR 112022021203A BR 112022021203 A BR112022021203 A BR 112022021203A BR 112022021203 A2 BR112022021203 A2 BR 112022021203A2
Authority
BR
Brazil
Prior art keywords
relates
proteins
antibodies
derivatives
pathway
Prior art date
Application number
BR112022021203A
Other languages
English (en)
Inventor
Shao Zhixin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022021203A2 publication Critical patent/BR112022021203A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MODULAÇÃO DE ENZIMA E VIA COM COMPOSTOS SULFIDRILA E SEUS DERIVADOS. A presente invenção refere-se a proteínas, particularmente anticorpos, tais como anticorpos biespecíficos anti-CD20/anti-CD3 e anticorpos anti-a-sinucleína, com glicanos monogalactosilados (G1) e digalactosilados (G2). Mais particularmente, a presente invenção refere-se à engenharia de galactosilação para gerar proteínas com propriedades terapêuticas melhoradas, incluindo proteínas com título aumentado. Além disso, a invenção refere-se a um meio de cultura de células e a uma célula de mamífero, bem como a métodos que utilizam o referido meio de cultura de células e a referida célula de mamífero para produzir as referidas proteínas. Além disso, a presente invenção refere-se à utilização dos referidos anticorpos como um medicamento tal como para o tratamento de câncer, particularmente câncer associado a células B ou doença de Parkinson.
BR112022021203A 2020-04-24 2021-04-23 Modulação de enzima e via com compostos sulfidrila e seus derivados BR112022021203A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20171356 2020-04-24
PCT/EP2021/060637 WO2021214277A1 (en) 2020-04-24 2021-04-23 Enzyme and pathway modulation with sulfhydryl compounds and their derivatives

Publications (1)

Publication Number Publication Date
BR112022021203A2 true BR112022021203A2 (pt) 2022-12-06

Family

ID=70464886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021203A BR112022021203A2 (pt) 2020-04-24 2021-04-23 Modulação de enzima e via com compostos sulfidrila e seus derivados

Country Status (17)

Country Link
US (1) US20230265204A1 (pt)
EP (2) EP4139349A1 (pt)
JP (1) JP2023522417A (pt)
KR (1) KR20230005172A (pt)
CN (1) CN115427443A (pt)
AR (1) AR121918A1 (pt)
AU (1) AU2021258475A1 (pt)
BR (1) BR112022021203A2 (pt)
CA (1) CA3178472A1 (pt)
CL (1) CL2022002885A1 (pt)
CR (1) CR20220531A (pt)
IL (1) IL296664A (pt)
MX (1) MX2022013173A (pt)
PE (1) PE20230078A1 (pt)
TW (1) TW202206459A (pt)
WO (1) WO2021214277A1 (pt)
ZA (1) ZA202210643B (pt)

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3334167A1 (de) 1983-09-21 1985-04-04 Siemens AG, 1000 Berlin und 8000 München Halbleiterdiode
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
EP1347493A3 (en) 1993-05-28 2005-11-23 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
JP2002502086A (ja) 1998-01-23 2002-01-22 アナリティカ オブ ブランフォード インコーポレーテッド 表面からの質量分光測定
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
NZ569490A (en) * 2001-12-27 2008-11-28 Glycofi Inc Methods to engineer mammalian-type carbohydrate structures
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
CN100509850C (zh) 2003-05-31 2009-07-08 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
SI2520590T1 (sl) 2007-04-03 2018-12-31 Amgen Research (Munich) Gmbh Posebna vezna domena za križanje vrst
EP2207881A1 (en) 2007-10-12 2010-07-21 F. Hoffmann-Roche AG Protein expression from multiple nucleic acids
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR101781228B1 (ko) 2008-12-19 2017-09-22 바이오겐 인터내셔널 뉴로사이언스 게엠베하 인간 항-알파-시누클레인 자가항체
KR20110013687A (ko) 2009-08-03 2011-02-10 삼성모바일디스플레이주식회사 유기전계발광표시장치 및 그의 구동방법
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
PT2748201T (pt) 2011-08-23 2018-02-08 Roche Glycart Ag Moléculas de ligação ao antigénio biespecíficas que ativam as células t
CN107880123A (zh) 2011-10-28 2018-04-06 普罗典娜生物科学有限公司 识别α‑突触核蛋白的人源化抗体
AU2013211874B2 (en) 2012-01-27 2017-11-02 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
PL3071597T3 (pl) 2013-11-21 2020-11-30 F.Hoffmann-La Roche Ag Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania
BR112016030462A2 (pt) 2014-08-04 2018-01-16 F. Hoffmann-La Roche Ag moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
MX2019014274A (es) * 2017-06-02 2020-01-23 Hoffmann La Roche Metodo de tratamiento.
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
CA3108986A1 (en) * 2018-08-09 2020-02-13 Ventana Medical Systems, Inc. Determination of parkinson's disease

Also Published As

Publication number Publication date
PE20230078A1 (es) 2023-01-11
AU2021258475A1 (en) 2022-10-20
EP4139349A1 (en) 2023-03-01
TW202206459A (zh) 2022-02-16
JP2023522417A (ja) 2023-05-30
AR121918A1 (es) 2022-07-20
MX2022013173A (es) 2022-11-30
ZA202210643B (en) 2023-06-28
IL296664A (en) 2022-11-01
CN115427443A (zh) 2022-12-02
WO2021214277A1 (en) 2021-10-28
CA3178472A1 (en) 2021-10-28
EP4400515A2 (en) 2024-07-17
CL2022002885A1 (es) 2023-06-16
EP4400515A3 (en) 2024-10-23
CR20220531A (es) 2022-11-28
US20230265204A1 (en) 2023-08-24
KR20230005172A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
Kouakanou et al. Vitamin C promotes the proliferation and effector functions of human γδ T cells
Pestana et al. No longer underappreciated: the emerging concept of astrocyte heterogeneity in neuroscience
BRPI0412153B8 (pt) anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal
Zhang et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
BR112020026125A8 (pt) Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
Li et al. Mesenchymal stem cells: characteristics, function, and application
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
Calkins et al. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage
Cao et al. Activation loop phosphorylation of a protein kinase is a molecular marker of organelle size that dynamically reports flagellar length
Yu et al. Inhibition of cell migration by focal adhesion kinase: Time-dependent difference in integrin-induced signaling between endothelial and hepatoblastoma cells
Song et al. Cardiomyocytes from phorbol myristate acetate-activated mesenchymal stem cells restore electromechanical function in infarcted rat hearts
Lăzărescu et al. Speleotherapy–modern bio-medical perspectives
BR112023020167A2 (pt) Fusões agente-ligante de ligação biespecífica para a degradação de proteínas alvo
Cheleschi et al. Hydrostatic pressure regulates oxidative stress through microRNA in human osteoarthritic chondrocytes
Grañé-Boladeras et al. Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir
Konířová et al. Differentiation induction as a response to irradiation in neural stem cells in vitro
Gualdani et al. How TRPC channels modulate hippocampal function
Xing et al. Roles of mitochondrial fusion and fission in breast cancer progression: a systematic review
Romeo et al. VPA and TSA interrupt the interplay between mutp53 and HSP70, leading to CHK1 and RAD51 down-regulation and sensitizing pancreatic cancer cells to AZD2461 PARP inhibitor
Codenotti et al. Hyperactive Akt1 signaling increases tumor progression and DNA repair in embryonal rhabdomyosarcoma RD line and confers susceptibility to glycolysis and mevalonate pathway inhibitors
BR112022021203A2 (pt) Modulação de enzima e via com compostos sulfidrila e seus derivados
Heinen et al. Effects of Lonomia obliqua caterpillar venom upon the proliferation and viability of cell lines
Yang et al. A new ex vivo method for effective expansion and activation of human natural killer cells for anti-tumor immunotherapy
Alkozi et al. TRPV4 stimulation induced melatonin secretion by increasing arylalkymine N-acetyltransferase (AANAT) protein level
Thomas et al. Low-dose hyper-radiosensitivity of progressive and regressive cells isolated from a rat colon tumour: impact of DNA repair